AU2020267661B2 - JAK inhibitors - Google Patents

JAK inhibitors

Info

Publication number
AU2020267661B2
AU2020267661B2 AU2020267661A AU2020267661A AU2020267661B2 AU 2020267661 B2 AU2020267661 B2 AU 2020267661B2 AU 2020267661 A AU2020267661 A AU 2020267661A AU 2020267661 A AU2020267661 A AU 2020267661A AU 2020267661 B2 AU2020267661 B2 AU 2020267661B2
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
solvate
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020267661A
Other languages
English (en)
Other versions
AU2020267661A1 (en
Inventor
Jason Harris
Raju Mohan
John Nuss
Shendong Yuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vimalan Biosciences Inc
Original Assignee
Vimalan Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vimalan Biosciences Inc filed Critical Vimalan Biosciences Inc
Publication of AU2020267661A1 publication Critical patent/AU2020267661A1/en
Application granted granted Critical
Publication of AU2020267661B2 publication Critical patent/AU2020267661B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
AU2020267661A 2019-05-08 2020-05-07 JAK inhibitors Active AU2020267661B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962845119P 2019-05-08 2019-05-08
US62/845,119 2019-05-08
US201962884588P 2019-08-08 2019-08-08
US62/884,588 2019-08-08
PCT/US2020/031925 WO2020227563A1 (en) 2019-05-08 2020-05-07 Jak inhibitors

Publications (2)

Publication Number Publication Date
AU2020267661A1 AU2020267661A1 (en) 2021-12-23
AU2020267661B2 true AU2020267661B2 (en) 2026-05-07

Family

ID=73051620

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020267661A Active AU2020267661B2 (en) 2019-05-08 2020-05-07 JAK inhibitors

Country Status (13)

Country Link
US (1) US11136329B2 (enExample)
EP (1) EP3966209A4 (enExample)
JP (1) JP7617030B2 (enExample)
KR (1) KR102916168B1 (enExample)
CN (1) CN114269734B (enExample)
AU (1) AU2020267661B2 (enExample)
BR (1) BR112021022380A2 (enExample)
CA (1) CA3139277A1 (enExample)
IL (1) IL287876A (enExample)
MX (1) MX2021013602A (enExample)
SG (1) SG11202112362YA (enExample)
TW (1) TWI865525B (enExample)
WO (1) WO2020227563A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269734B (zh) 2019-05-08 2026-03-27 维玛兰生物科学公司 Jak抑制剂
CA3150281A1 (en) 2019-08-08 2021-02-11 Vimalan Biosciences, Inc. Jak inhibitors
CN114644633B (zh) * 2020-12-18 2026-02-03 北京诺诚健华医药科技有限公司 杂环类jak抑制剂
KR102637915B1 (ko) * 2021-06-25 2024-02-19 한국화학연구원 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ｃｋ１２抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140222A2 (en) * 2006-05-26 2007-12-06 Novartis Ag Pyrrolopyrimidine compounds and their uses
WO2010020675A1 (en) * 2008-08-22 2010-02-25 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
WO2011048082A1 (en) * 2009-10-20 2011-04-28 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
WO2011134831A1 (en) * 2010-04-30 2011-11-03 Cellzome Limited Pyrazole compounds as jak inhibitors
WO2012143320A1 (en) * 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801971A (zh) 2005-09-30 2010-08-11 沃泰克斯药物股份有限公司 可用作janus激酶抑制剂的脱氮嘌呤
AU2008211172A1 (en) 2007-01-30 2008-08-07 Biogen Idec Ma Inc. 1-H-pyrazolo(3,4B)pyrimidine derivatives and their use as modulators of mitotic kinases
UY31631A1 (es) 2008-02-06 2009-09-30 Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones
WO2011156698A2 (en) 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
KR20140063700A (ko) * 2011-09-20 2014-05-27 셀좀 리미티드 키나제 억제제로서의 피라졸로[4,3-c]피리딘 유도체
EA025186B1 (ru) 2012-06-29 2016-11-30 Пфайзер Инк. НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2
BR112017027951A2 (pt) 2015-06-22 2018-08-28 Ono Pharmaceutical Co., Ltd. composto inibitório de brk
CN108864057B (zh) * 2017-05-16 2020-03-31 山东大学 含有4-氨基吡唑结构的jak与hdac双靶点抑制剂及其制备方法和应用
CN114269734B (zh) 2019-05-08 2026-03-27 维玛兰生物科学公司 Jak抑制剂
CA3150281A1 (en) 2019-08-08 2021-02-11 Vimalan Biosciences, Inc. Jak inhibitors
EP4034107A4 (en) 2019-09-25 2023-08-30 Vimalan Biosciences, Inc. JAK INHIBITORS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140222A2 (en) * 2006-05-26 2007-12-06 Novartis Ag Pyrrolopyrimidine compounds and their uses
WO2010020675A1 (en) * 2008-08-22 2010-02-25 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
WO2011048082A1 (en) * 2009-10-20 2011-04-28 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
WO2011134831A1 (en) * 2010-04-30 2011-11-03 Cellzome Limited Pyrazole compounds as jak inhibitors
WO2012143320A1 (en) * 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors

Also Published As

Publication number Publication date
BR112021022380A2 (pt) 2022-03-22
MX2021013602A (es) 2022-04-06
US20200369669A1 (en) 2020-11-26
EP3966209A1 (en) 2022-03-16
CA3139277A1 (en) 2020-11-12
JP2022532877A (ja) 2022-07-20
WO2020227563A1 (en) 2020-11-12
AU2020267661A1 (en) 2021-12-23
TW202108587A (zh) 2021-03-01
TWI865525B (zh) 2024-12-11
CN114269734A (zh) 2022-04-01
EP3966209A4 (en) 2023-01-04
CN114269734B (zh) 2026-03-27
IL287876A (en) 2022-01-01
US11136329B2 (en) 2021-10-05
KR20220052859A (ko) 2022-04-28
SG11202112362YA (en) 2021-12-30
JP7617030B2 (ja) 2025-01-17
KR102916168B1 (ko) 2026-01-21

Similar Documents

Publication Publication Date Title
US11780842B2 (en) TYK2 pseudokinase ligands
JP7635228B2 (ja) Ｔｙｋ２偽キナーゼリガンド
US11136329B2 (en) JAK inhibitors
AU2020218267A1 (en) TYK2 pseudokinase ligands
US9783552B2 (en) Soluble guanylate cyclase activators
WO2021062036A1 (en) Jak inhibitors
US11459333B2 (en) Substituted pyrrolo[2,3-d]pyrimidines as JAK inhibitors
HK40072097A (en) Jak inhibitors
HK40080624A (en) Jak inhibitors

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO REQUEST EXAMINATION HAS BEEN EXTENDED TO 13 JUN 2024